Electromed, Inc.
24.01-0.43 (-1.76%)
Oct 29, 4:00:00 PM EDT · NYSE American · ELMD · USD
Key Stats
Market Cap
201.11MP/E (TTM)
28.25Basic EPS (TTM)
0.85Dividend Yield
0%Recent Filings
8-K
Electromed approves $10M buyback
Electromed's board authorized a $10.0 million share repurchase program on September 9, 2025, following the depletion of its prior authorization in fiscal 2025's fourth quarter. This move, backed by strong operational performance and ample cash reserves, aims to boost shareholder value through open-market or negotiated buys, timed to market conditions. Repurchases underscore confidence in the company's trajectory. Yet risks like reimbursement hurdles loom.
8-K
Record revenue, income growth
Electromed reported record fiscal 2025 results on August 26, 2025, with net revenue surging 17.0% to $64.0 million and operating income climbing 46.8% to $9.7 million, fueled by expanded direct sales and higher approvals in homecare. Gross margins improved to 78.1%, while the company repurchased $10.0 million in shares, bolstering its debt-free balance sheet with $15.3 million cash. Growth persists. Yet reimbursement risks loom large.
10-K
FY2025 results
Electromed's FY2025 revenue surged 17% to $64M, driven by 15.7% homecare growth to $57.3M and 23.9% hospital gains to $3.1M, with Q4 momentum from expanded sales reps boosting approvals and net revenue per device. Gross margins expanded to 78.1% amid higher volumes, while operating income climbed 46.8% to $9.7M, fueled by efficient scaling yet tempered by $3.1M in share-based comp. Cash from operations hit $11.4M, supporting $10M in buybacks that exhausted authorizations. No FY2026 guidance disclosed. Reimbursement shifts from OBBBA could squeeze quarterly margins.
8-K
Q3 revenue up 13.1%
Electromed reported Q3 fiscal 2025 results on May 13, 2025, with net revenue up 13.1% to $15.7 million, driven by 14.8% growth in direct homecare to $14.1 million from more sales reps and reimbursement efficiencies. Operating income rose 16.2% to $2.1 million, while net income climbed 26.7% to $1.9 million, or $0.21 per diluted share. The board authorized a $5 million stock repurchase, signaling confidence amid strong cash flow of $7.5 million for the nine months. Revenue keeps climbing.
10-Q
Q3 FY2025 results
Electromed posted solid Q3 FY2025 results, with net revenues climbing 13.1% year-over-year to $15.7M, fueled by a 14.8% jump in homecare sales to $14.1M from more referrals and reimbursement tweaks, while gross margins expanded to 78.0% from 74.8% on higher revenue per device. Operating income rose 16.2% to $2.1M, and diluted EPS hit $0.21, up from $0.17, reconciling cleanly with 8.97M weighted shares. Cash from operations reached $7.5M over nine months, yielding $7.4M free cash flow after $0.1M capex (derived), though share repurchases totaling $6.3M trimmed cash to $15.2M; the $2.5M revolver remains fully available with no debt. No M&A or impairments noted. Reimbursement hurdles from Medicare and private payers pose ongoing risks.
CNMD
CONMED Corporation
46.71-0.61
DYNT
Dynatronics Corp.
0.05+0.00
EBRCZ
EBR SYSTEMS INC NPV CDI 1:1
0.95+0.00
ECOR
electroCore, Inc.
5.04+0.13
EMED
Electromedical Technologies, In
0.00+0.00
INSP
Inspire Medical Systems, Inc.
75.17-2.00
RMD
ResMed Inc.
253.62-2.95
RMSL
RemSleep Holdings, Inc.
0.00+0.00
TCMD
Tactile Systems Technology, Inc
15.18-0.17
VMD
Viemed Healthcare, Inc.
6.54-0.32